Published in Antimicrob Agents Chemother on September 01, 2005
Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol (2008) 1.86
Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicrob Agents Chemother (2008) 1.37
Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico. J Clin Microbiol (2007) 1.17
Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.11
Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review. J Pediatr Pharmacol Ther (2009) 1.09
Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrob Agents Chemother (2009) 1.03
High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2011) 0.99
Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother (2014) 0.88
Accessory Gene Regulator Polymorphism and Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus. Ann Lab Med (2015) 0.75
Vancomycin dosage regimens for pediatric patients. J Pediatr Pharmacol Ther (2009) 0.75
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol (1998) 6.26
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother (2001) 5.83
Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol (2001) 4.18
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet (1998) 4.08
Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis (2003) 3.39
Infective endocarditis. Clin Infect Dis (1993) 2.52
Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet (1999) 2.30
Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis (2004) 1.73
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents (2000) 1.43
Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust (2001) 1.15
Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn Microbiol Infect Dis (2003) 0.85
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother (2001) 5.83
Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol (2001) 4.18
Sequence analysis of the L1 metallo-beta-lactamase from Xanthomonas maltophilia. Biochim Biophys Acta (1994) 3.52
The crystal structure of the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia at 1.7 A resolution. J Mol Biol (1998) 3.24
Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. Neurology (2002) 3.13
Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA (1999) 3.13
Screening of urines with dipstrips: does it reduce workload and consumable costs? J Clin Pathol (1990) 2.68
EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect (2011) 2.65
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
Importance of air quality and related factors in the prevention of infection in orthopaedic implant surgery. J Hosp Infect (1998) 2.17
Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother (1997) 2.07
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. J Antimicrob Chemother (2012) 2.04
Comment on: Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother (2007) 1.99
Needlestick injuries among medical students. J Hosp Infect (1993) 1.96
Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2001) 1.87
Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol (2008) 1.86
Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis (2004) 1.84
Overexpression, purification, and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother (1998) 1.73
Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase. J Biol Chem (2001) 1.61
Salt tolerance of EMRSA-16 and its effect on the sensitivity of screening cultures. J Hosp Infect (1997) 1.60
In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect (1999) 1.57
Vancomycin-resistant Staphylococcus aureus. Lancet (1998) 1.57
Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam. Br J Urol (1995) 1.56
Listeria monocytogenes and its role in human infection. J Infect (1988) 1.54
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect (2012) 1.53
Contamination of wounds by direct inoculation in total hip arthroplasty: a prospective clinical study. J Hosp Infect (1998) 1.52
Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections. BMJ (1994) 1.52
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin Microbiol Infect (2006) 1.45
Use of antimicrobial agents in veterinary medicine and food animal production. Int J Antimicrob Agents (2001) 1.40
Escherichia coli CreBC is a global regulator of gene expression that responds to growth in minimal media. J Biol Chem (2001) 1.38
Molecular characterization of VIM-producing Klebsiella pneumoniae from Scandinavia reveals genetic relatedness with international clonal complexes encoding transferable multidrug resistance. Clin Microbiol Infect (2011) 1.38
A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible beta-lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity. J Antimicrob Chemother (1995) 1.38
Sequence analysis of two chromosomally mediated inducible beta-lactamases from Aeromonas sobria, strain 163a, one a class D penicillinase, the other an AmpC cephalosporinase. J Antimicrob Chemother (1995) 1.37
blaNDM-1 is a chimera likely constructed in Acinetobacter baumannii. Antimicrob Agents Chemother (2012) 1.37
Antimicrobial chemotherapy of human infection due to Listeria monocytogenes. Eur J Clin Microbiol Infect Dis (1995) 1.33
Prophylactic oral fluconazole and candida fungaemia. Lancet (1991) 1.33
Nucleotide and amino acid sequences of the metallo-beta-lactamase, ImiS, from Aeromonas veronii bv. sobria. Antimicrob Agents Chemother (1998) 1.29
Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. J Antimicrob Chemother (1999) 1.28
Heterogeneous resistance to vancomycin in Staphylococcus aureus. J Antimicrob Chemother (2000) 1.28
A TEM-2beta-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J Antimicrob Chemother (2000) 1.26
Expression of lux genes in a clinical isolate of Streptococcus pneumoniae: using bioluminescence to monitor gemifloxacin activity. Antimicrob Agents Chemother (2002) 1.25
Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother (2002) 1.24
Clothing in laminar-flow operating theatres. J Hosp Infect (1996) 1.23
Distribution and expression of beta-lactamase genes among Aeromonas spp. J Antimicrob Chemother (1997) 1.22
A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. J Antimicrob Chemother (1992) 1.21
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother (2002) 1.21
A prospective, randomised trial of prophylactic antibiotics versus bag extraction in the prophylaxis of wound infection in laparoscopic cholecystectomy. Ann R Coll Surg Engl (2000) 1.20
Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria. Clin Microbiol Infect (2001) 1.17
Streptococcus milleri and second trimester abortion. J Clin Pathol (1987) 1.17
Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother (2000) 1.17
Once-daily aminoglycoside dosing. Lancet (1993) 1.15
A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J Antimicrob Chemother (2001) 1.12
Heterogeneity at the beta-lactamase structural gene ampC amongst Citrobacter spp. assessed by polymerase chain reaction analysis: potential for typing at a molecular level. J Med Microbiol (1994) 1.12
Carriage of antibiotic-resistant bacteria by healthy children. J Antimicrob Chemother (2001) 1.11
Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility. J Clin Microbiol (1999) 1.09
Use of a clinical Escherichia coli isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin. J Antimicrob Chemother (1999) 1.09
Enzyme kinetics and biochemical analysis of ImiS, the metallo-beta-lactamase from Aeromonas sobria 163a. J Antimicrob Chemother (1996) 1.09
Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob Agents Chemother (1996) 1.06
Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains. Biochim Biophys Acta (2005) 1.05
Human peritoneal macrophage phagocytic, killing, and chemiluminescent responses to opsonized Listeria monocytogenes. Infect Immun (1983) 1.05
Purine nucleoside phosphorylase: a new marker for free oxygen radical injury to the endothelial cell. Hepatology (1990) 1.04
Characterization, cloning and sequence analysis of the inducible Ochrobactrum anthropi AmpC beta-lactamase. J Antimicrob Chemother (2001) 1.00
Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother (2003) 1.00
The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria. J Antimicrob Chemother (1996) 0.99
Aeromonas hydrophila AmpH and CepH beta-lactamases: derepressed expression in mutants of Escherichia coli lacking creB. J Antimicrob Chemother (2000) 0.97
Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net. J Antimicrob Chemother (1997) 0.95
Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. J Antimicrob Chemother (2010) 0.95
Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. J Antimicrob Chemother (1999) 0.94
BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J Antimicrob Chemother (2002) 0.93
Point of care testing for urinary tract infection in primary care (POETIC): protocol for a randomised controlled trial of the clinical and cost effectiveness of FLEXICULT™ informed management of uncomplicated UTI in primary care. BMC Fam Pract (2014) 0.92
A review of the clinical presentation, laboratory features, antimicrobial therapy and outcome of 77 episodes of pneumococcal meningitis occurring in children and adults. J Infect (1994) 0.91
NDM-1 polymicrobial infections including Vibrio cholerae. Lancet (2012) 0.91
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus. FEBS Lett (2001) 0.90
A 10 year survey of the epidemiology and clinical aspects of listeriosis in a provincial English city. J Infect (1994) 0.89
In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. J Antimicrob Chemother (1999) 0.88
The problem of a solvent exposable disulfide when preparing Co(II)-substituted metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. J Biol Inorg Chem (2001) 0.88
Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. J Antimicrob Chemother (1998) 0.88
In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J Antimicrob Chemother (2002) 0.87
A critical assessment of the agar dilution chequerboard technique for studying in-vitro antimicrobial interactions using a representative beta-lactam, aminoglycoside and fluoroquinolone. J Antimicrob Chemother (1995) 0.87
Serum monitoring of teicoplanin. J Antimicrob Chemother (1992) 0.87
Cefuroxime resistance in Haemophilus influenzae. Lancet (1992) 0.86
The use and therapeutic drug monitoring of teicoplanin in the UK. Clin Microbiol Infect (2004) 0.86
Clostridia and neutropenic enterocolitis. Lancet (1988) 0.86
beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother (2000) 0.86
Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin's lymphoma. J Infect (1994) 0.86
Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother (2010) 0.86
Therapeutic monitoring of antimicrobials: a summary of the information presented at the UK NEQAS for antibiotic Assays meeting for participants, October 1993. J Antimicrob Chemother (1995) 0.85
[Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy]. Pathol Biol (Paris) (2002) 0.85
Detection of extended-spectrum beta-lactamases with Etest and double-disc potentiation methods. J Antimicrob Chemother (2000) 0.85
Corynebacterium CDC group D2 bacteraemia. J Clin Pathol (1987) 0.85
A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure. Drugs (1987) 0.85
Detection of glycopeptide resistance in Staphylococcus aureus. J Antimicrob Chemother (2001) 0.85
The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. J Antimicrob Chemother (1988) 0.85